

4 June 2026

ASX Announcement

Galidesivir GMP manufacturing underway to support pivotal study and broader biodefence opportunities

- **GMP manufacturing of Galidesivir commenced to support pivotal Marburg study under US FDA's Animal Rule pathway**
- **GMP-grade Galidesivir to be manufactured by global CRDMO PI Health Sciences ("PIHS")**
- **Pivotal study initiatives expected to represent final requirements prior to potential FDA submission**
- **Existing Galidesivir inventory remains available for planned dose optimisation studies – Agreements with trial partners imminent**
- **Agreement and GMP supply establish manufacturing, analytical and quality systems required for future regulatory and procurement activities**
- **Enhances Island's ability to pursue near-term biodefence and outbreak response opportunities, including current Ebola outbreak**
- **Significant milestone in Galidesivir's progression towards commercialisation as a medical and biodefence countermeasure for high-consequence viral threats**

MELBOURNE Australia, 4 June 2026: Australian antiviral drug development and biodefence company, Island Pharmaceuticals Ltd (**ASX: ILA; Island or the Company**) is pleased to announce it has executed an agreement with PI Health Sciences ("PIHS") for a GMP manufacturing campaign that includes analytical method validation, reference standard preparation, stability studies and the manufacture of Galidesivir to support pivotal studies.

The agreement represents a major step in Island's strategy to advance Galidesivir as a countermeasure for Marburg Virus Disease and other high-consequence viral threats. The program establishes the manufacturing and quality infrastructure required to support future pivotal efficacy studies, human safety studies, regulatory submissions and government procurement opportunities, while ensuring the Company maintains access to GMP-grade product for emerging biodefence and outbreak response initiatives.

Importantly, while Galidesivir has been manufactured previously, this campaign is designed to validate and scale production to a level appropriate for late-stage development, representing a key step in the transition from a development-stage asset to a potential biodefence product.

Manufacturing activities have commenced and Island expects to receive GMP-grade Galidesivir in the coming months. The manufactured product will support the Company's planned Marburg development program under the US Food & Drug Administration's (FDA) Animal Rule pathway.

The GMP grade product will be specifically used for the Company's planned pivotal study which will contribute to the final clinical steps prior to FDA submission, while pending dose optimisation studies will utilise Island's existing Galidesivir supply.



In parallel, the availability of GMP-grade Galidesivir will position the Company to advance additional near-term opportunities across biodefence, pandemic preparedness and emerging infectious disease programs, including recent Ebola outbreaks.

Manufacturing is being undertaken by PIHS, a global contract research, development and manufacturing organisation specialising in the development and manufacture of active pharmaceutical ingredients for regulated markets. Through facilities across Europe and Asia, PIHS provides analytical development, process optimisation and GMP manufacturing services to biotechnology and pharmaceutical companies globally. The company operates GMP compliant manufacturing facilities and has extensive experience supporting products through clinical development and commercialisation.

Beyond Marburg, the availability of GMP-grade Galidesivir is expected to provide strategic flexibility to advance additional biodefence and infectious disease opportunities. Galidesivir has previously demonstrated broad-spectrum antiviral activity against multiple RNA virus families, including Ebola. With renewed global attention on biodefence preparedness and the emergence of new viral outbreaks, maintaining access to clinical-grade drug supply represents an increasingly important strategic asset.

The commencement of GMP manufacturing marks the transition of Galidesivir from a legacy antiviral asset into an actively advancing biodefence program, with the key components required for future pivotal studies, regulatory engagement and potential government procurement pathways now being assembled.

Management commentary:

CEO and Managing Director, Dr David Foster said: *"The commencement of GMP manufacturing is a significant milestone and represents another important step in the commercialisation pathway for Galidesivir.*

Importantly, Island already has sufficient Galidesivir supply to support our planned dose optimisation studies. The material being manufactured under this agreement is intended for the pivotal efficacy study that is expected to form the cornerstone of a future FDA submission under the Animal Rule pathway.

As we advance our clinical trial pathway for Marburg, we are becoming increasingly focussed on concurrently assembling the manufacturing, quality and regulatory framework required to support potential approval and procurement. This program is a key component of that transition.

Beyond supporting the Marburg program, establishing a supply of GMP-grade Galidesivir significantly enhances our strategic flexibility. As governments around the world continue to strengthen biodefence preparedness and respond to emerging infectious disease threats including the current Bundibugyo Ebola outbreak, maintaining access to clinical-grade product allows Island to engage rapidly with potential opportunities as they arise.

With manufacturing now underway, access to non-human primates close to finalised, and our regulatory pathway continuing to take shape, we are systematically building the critical elements required to position Galidesivir as a potential countermeasure for Marburg Virus Disease and other high-consequence viral threats."

- Ends -

Approved for release to the ASX by:



The Board of Island Pharmaceuticals Limited
info@islandpharmaceuticals.com

Investors and media, for further information, please contact:

Henry Jordan
Six Degrees Investor Relations
+61 (0) 431 271 538
henry.jordan@sdir.com.au

About Island Pharmaceuticals

Island (ASX: ILA) is focused on areas of unmet need for drugs that can address urgent viral diseases, public health or biosecurity threats. The Company is executing a dual development strategy for its assets, ISLA-101 and Galidesivir.

ISLA-101 has a well-established safety profile, being repurposed for the prevention and treatment of dengue fever and other mosquito (or vector) borne diseases. Galidesivir is a clinical-stage antiviral molecule with a broad spectrum of activity in over 20 RNA viruses, including high-priority threats such as Ebola, Marburg, MERS, Zika and Yellow fever – viruses with significant unmet medical needs and that may contribute to national security threats.

Island encourages all current investors to go paperless by registering their details with the Company's share registry, Automatic Registry Services, whose contact info is housed on the Shareholder Services page of the Company's website.

Visit www.islandpharmaceuticals.com for more on Island.

For personal use only